Are There Refill Maximums for GLP-1 Prescriptions?

“Lifetime limits are dictated by insurance and whether it is used for diabetes management versus medical weight loss.”

GLP-1 prescription medications are generally covered for as long as your physician deems the drug to be medically necessary for treating your condition, provided you meet your insurance plan’s prior-authorization requirements. So, instead of setting a number as “the fill limit,” each health insurance provider or employer-based healthcare plan can place their own cap on coverage, which then depends upon whether the medication is prescribed for managing type 2 diabetes or is being used as a weight loss drug for treating obesity.

If glucagon-like peptide-1 (semaglutide) or glucagon-like peptide-1 combined with glucose-dependent insulinotropic polypeptide (tirzepatide) are prescribed for weight management, employer-sponsored programs or private health plans may impose “fill maximums” that limit the number of refills a patient can receive in his or her lifetime, such as two dozen 1-month refills over a span of two years. In most cases, limits are directly related to an individual patient’s diagnosis and whether the medications are used to manage diabetes versus weight loss.

How long a patient will need to take a prescriptive GLP-1 weight loss medication does directly depend upon the doctor’s maintenance strategy to manage a diabetic’s HbA1c blood sugar levels or for a patient to reach established weight loss goals. Although diabetes medications may require adjustments throughout the treatment process, experts usually agree that various drugs will be needed for long-term maintenance of the disease. On the other hand, dosage or use of GLP-1 medications can vary significantly when maintaining a target weight.

Does Medicare Part D cover GLP-1s for weight loss?

Currently, Standard Medicare Part D coverage usually excludes weight loss drugs, but it may be covered if the patient’s doctor prescribes a GLP-1 medication for an FDA-approved health condition, such as long-term treatment for obesity. In addition, older adults who are eligible may qualify for the temporary GLP-1 Bridge Program that provides coverage up to eighteen months with a monthly copayment of $50. Annual out-of-pocket maximum prescription deductibles are capped at $2,100 for Standard Medicare Part D. Nonetheless, if the GLP-1 medication is prescribed for the ongoing treatment of Type 2 diabetes, both primary and secondary carriers may provide coverage for long-term maintenance therapy without lifetime limits.

How much GLP-1 will you need to take?

The quick answer to your question is it depends. Dosing frequency, formulations and the actual dosage for glucagon-like peptide-1 receptor agonists can vary significantly based on the medical condition being treated (indication) as well as the patient’s specific needs. For example, if a patient is more sensitive to the medication’s side effects, titration may be needed with gradual dose-escalation schedules to minimize gastrointestinal side effects like nausea or vomiting, to support kidney function, or to co-exist with a patient’s current medications. Actual dosage and the strength of each dose may vary, where the same formulation may require lower-dosing for one condition but a much higher-dosage for another.

Why are there different types of GLP-1 medications?

While different types of GLP-1 medications do exist, all mimic the gut hormones that naturally regulate blood sugar levels and help curb appetite, as well as provide additional metabolic benefits. Single GLP-1 receptor agonists like semaglutide only target the GLP-1 pathway that acts on specific receptors in the pancreas, brain and stomach. Dual agonists like tirzepatide also target a secondary hormone called glucose-dependent insulinotropic polypeptide (GIP) to yield stronger results. The most common single and dual-action receptor agonists include: liraglutide (older GLP-1 that requires daily injections), semaglutide (a newer GLP-1 with a once-weekly injection or daily pill), tirzepatide (dual action GLP-1/GIP taken weekly tends to yield more significant results), and dulaglutide (once-weekly GLP-1 injectable for insulin management that is not FDA-approved for weight loss but that triggers pancreatic insulin when blood sugar is high).

So Which GLP-1 Weight Loss Drug Is Best for Me?

Since both single-action and dual-action receptor agonists are both highly potent, your medical provider will usually target the lowest effective dose to manage your specific condition with the fewest side effects. Plus, dosing levels are typically titrated and increase more gradually over several weeks of time to minimize unwanted gastrointestinal side effects. Ultimately, it is the patient who works directly with their provider and one-on-one coach to make a highly personal decision based on their overall metabolic health, drug side effects, and cost.

Generally speaking, medical experts view GLP-1s as a long-term treatment option for managing blood sugar levels. However, stopping use of the drug completely will likely require significant adjustments to other diabetes medications to prevent A1C levels from returning to pre-treatment levels. Although the FDA does approve both single and dual-action GLP-1s for chronic weight management, once a patient reaches their weight loss goals, their doctor will most likely lower overall dosage to sustain the target weight while minimizing side effects.

If a patient’s goal is to discontinue use of a GLP-1 medication after they reach their target weight, their doctor may recommend tapering rather than an abrupt cessation. Experts today generally compare obesity medications to drugs that are used to manage high blood pressure, in that they should be continued indefinitely for optimal metabolic wellness. On the flip side, others say some patients can successfully drop GLP-1 medications with robust multidisciplinary support with lifestyle changes, such as a protein-forward diet and resistance training.

________________________

Since medical opinions are mixed regarding lifetime usage of single or dual-action GLP-1 receptor agonists, it is important for men and women to work closely with their healthcare provider to map out a long-term plan that fits both their needs and lifestyle. Because obesity (and type 2 diabetes) are chronic conditions, simply stopping the medication may trigger biological urges to overeat, which can quickly lead to weight regain. In fact, if a patient decides to discontinue use of the GLP-1 once a target is reached, it will likely require establishing lifelong habits as well as possibly using non-GLP-1 medications to avoid regaining the “lost weight”. At Metabolic Research Center Dothan, our goal is to provide the one-on-one support needed to create a customized program that preserves crucial muscle mass, limits the common side effects of using a GLP-1, and produces the changes your body needs for long-term weight control.